Digest Network Come funziona
Network
/
Società
Fr
Non verificato

Fresenius Kabi

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaSaluteSanità

35 comunicati stampa

Guarda tutti i comunicati
20/01/2026
Fresenius Kabi Recognized as a Top Employer in the United States for the Fourth Consecutive Year
Fonte
Fresenius Kabi
Emittente
Business Wire
1.00
0
14/01/2026
Multimedialità
Industria
Igiene alimentare
Biotecnologia
Salute
Farmaceutica
Sanità
Oncologia
Mercato del lavoro
Fresenius Kabi, TQ Therapeutics Announce Cell Therapy Technology Agreement
Fonte
Fresenius Kabi
Emittente
Business Wire
1.00
0
06/01/2026
Fresenius Kabi Introduces New Presentation of Otulfi® (ustekinumab-aauz), a Biosimilar to Stelara®
Fonte
Fresenius Kabi
Emittente
Business Wire
1.00
0
18/12/2025
Fresenius Kabi Introduces First-Ever Rocuronium Bromide Injection Stable at Room Temperature
Fonte
Fresenius Kabi
Emittente
Business Wire
1.00
0
02/12/2025
Fresenius Kabi Expands Operating Room Portfolio with New Simplist® Prefilled Syringes
Fonte
Fresenius Kabi
Emittente
Business Wire
1.00
0
24/11/2025
Fresenius Kabi Introduces Dalbavancin for Injection (for single-dose regimen use only)
Fonte
Fresenius Kabi
Emittente
Business Wire
1.00
0
12/11/2025
Industria
Medicina - Varie
Biotecnologia
Biologia
Sanità
Farmaceutica
Salute
Oncologia
Fresenius Kabi’s Adaptive Nomogram used on Aurora Xi Plasmapheresis System Now Operating Nationwide at BioLife Plasma Centers
Fonte
Fresenius Kabi
Emittente
Business Wire
1.00
0
12/11/2025
CORRECTING and REPLACING Fresenius Kabi Issues Voluntary Nationwide Recall of Three Lots of Famotidine Injection, USP, 20 mg per 2 mL (10 mg per mL), 2 mL Fill in a 2 mL Vial Due to Out-of-Specification Endotoxin Results in Certain Reserve Samples
Fonte
Fresenius Kabi
Emittente
Business Wire
1.00
0
07/11/2025
Fresenius Kabi Issues Voluntary Nationwide Recall of Three Lots of Famotidine Injection, USP, 20 mg per 2 mL (10 mg per mL), 2 mL Fill in a 2 mL Vial Due to Out-of-Specification Endotoxin Results in Certain Reserve Samples
Fonte
Fresenius Kabi
Emittente
Business Wire
1.00
0
29/10/2025
Industria
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Oncologia
FDA Grants Interchangeable Designation to Fresenius Kabi’s Biosimilars Conexxence® and Bomyntra® (denosumab-bnht)
Fonte
Fresenius Kabi
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0